Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT

The fluoropyrimidine antimetabolites were employed in a wide range of neopl astic diseases. In particular, 8-fluorouracil in association with other che motherapeutic agents, or biochemical modulators was successfully used in th e treatment of colorectal, gastric, breast, head and neck cancers. With thi s type of chemotherapy, a response rate less than or equal to 20% was obtai ned in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantag e of an improved oral bioavailability, if we compare it with B-fluorouracil . Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In partic ular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, consid ering the possibility to administer it orally.